[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-neuropathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,72,100,133,158,185,216,244,267,289],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100639260","tscs-and-ar-training-on-qol-and-physical-activity-in-diabetic-neuropathy-patients-100639260",false,"NCT07619755","tSCS and AR Training on QoL and Physical Activity in Diabetic Neuropathy Patients","Combined Effects of Transcutaneous Spinal Cord Stimulation (tSCS) and Augmented Reality (AR) Training on Quality of Life (QoL) and Physical Activity in Diabetic Neuropathy Patients","Inclusion Criteria:\n\n* More than or equals to 4 scores on Douleur Neuropathique 4 Questionnaire (DN4)\n* More than or equals to 6 Hz at Neurothesiometer\n\nExclusion Criteria:\n\n* Cognitively compromised (MOCA score ≤ 26\u002F30)\n* Metallic implants at skull\n* Shunting\n* Skin allergy","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"NA","Existing evidence of tSCS emphasizes pain relief and overlooks other functional parameters such as sensory enhancement, lower limb flexibility, and sustained improvements in physical activity and QoL.\n\nCombined effects of tSCS and AR training on lower limb flexibility, vibration sense, QoL, and physical activity in patients with diabetic neuropathy. This dual approach has the potential to deliver a comprehensive strategy for managing DPN, which is low-cost, safe, and a more accessible solution for diabetic patients in Pakistan and around the world.",[26],"Diabetic Neuropathy",[28,29,30,31],"neuropathy","transcutaneous spinal cord stimulation","quality of life","augmented reality","NOT_YET_RECRUITING","2026-06-01",{"date":35,"type":36},"2026-06-02","ACTUAL",{"date":38,"type":20},"2026-06-15",{"date":40,"type":20},"2027-01-31",{"name":42,"class":43},"Riphah International University","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100637553","comparative-effects-of-perturbation-based-balance-training-on-firm-surface-and-rolling-board-for-diabetic-neuropathy-patients-100637553","NCT07598513","Comparative Effects of Perturbation-Based Balance Training on Firm Surface and Rolling Board for Diabetic Neuropathy Patients","Inclusion Criteria:\n\n* Individuals with a confirmed clinical diagnosis of Type 2 diabetes (HbA1c ≥ 6.5%) (Bolen et al., 2016).\n* Participants with a diabetes duration of more than 10 years (Grewal et al., 2015).\n* Participants exhibiting signs and symptoms of diabetic peripheral neuropathy (such as numbness, tingling, burning, shooting or electric shock-like pain, and glove-and-stocking distribution), confirmed using the Michigan Neuropathy Screening Instrument with scores of 6-8 (patient version) and 2.5-4 (physical assessment) (Haque et al., 2022).\n* Participants aged between 40 and 75 years (Rasool et al., 2024).\n* Both male and female participants will be eligible for inclusion (Haleem et al., 2024).\n* Participants currently using insulin-sensitizing medications (e.g., metformin, Diamicron, insulin).\n* Participants who are able to stand and walk independently (Allin et al., 2020).\n* Participants with a Berg Balance Scale score ranging from 25 to 40 (Phyu et al., 2022).\n* Participants willing to provide informed consent (Lepesis et al., 2023).\n\nExclusion Criteria:\n\n* Patients with a confirmed diagnosis of benign paroxysmal positional vertigo (BPPV) will be excluded (Daud et al., 2021).\n* Those with cognitive deficits (such as dementia or Alzheimer's disease) that may interfere with comprehension or compliance with study procedures will not be included (Hatton et al., 2019).\n* Individuals presenting with foot drop or other neurological disorders (e.g., stroke, myelopathy, or cerebellar ataxia) that could affect the study findings will be excluded (Khurshid et al., 2025).\n* Patients who have recently undergone surgery, sustained trauma to the feet or lower limbs, or have any foot amputation will not be eligible (Collings et al., 2023).\n* Individuals diagnosed with deep vein thrombosis or orthostatic hypotension will be excluded (Khurshid et al., 2025).\n* Patients with active diabetic foot ulcers or notable musculoskeletal deformities (such as scoliosis or degenerative joint disease) will be excluded (Lepesis et al., 2023).\n* Individuals with neuropathy unrelated to diabetes, including cases associated with alcohol use or Charcot-Marie-Tooth disease, will not be included.\n* Participants taking medications that may provoke vertigo or disturb balance (for example, aspirin) will be excluded.","40 Years","75 Years",{"count":53,"type":20},42,[23],"The present study is designed to compare the effectiveness of perturbation-based balance training performed on two different surfaces, stable (firm surface) and unstable (rolling board), for enhancing static, dynamic, and reactive balance in individuals diagnosed with diabetic neuropathy. This randomized clinical trial will recruit a total of 42 participants, with the sample size calculated using Epi Tool software. A consecutive sampling technique will be implemented. Eligible participants who fulfill the inclusion criteria will be randomly assigned into two equal groups (n = 21 each) through an online randomization method. Participants in Group A will undergo perturbation-based balance exercises on a stable surface, whereas participants in Group B will receive similar training on a rolling board to introduce surface instability. In addition to the primary intervention, both groups will receive contrast bath therapy as a standard baseline treatment. Written as well as verbal informed consent will be obtained prior to participation. The intervention protocol will span four weeks, consisting of three sessions per week on alternate days, resulting in a total of twelve treatment sessions. The primary outcomes will focus on balance performance and fall risk. These outcomes will be measured using the Berg Balance Scale, the Mini-Balance Evaluation Systems Test, and the Timed Up and Go test. Screening for diabetic neuropathy will be carried out using the Michigan Neuropathy Screening Instrument. Statistical analysis will be performed using SPSS version 23.",[57,26],"Balance Impairment",[26,59,60,61,62],"Balance","Perturbation-Based Balance Training","Mini-BESTest","Michigan Neuropathy Screening Instrument","2026-05-13",{"date":65,"type":36},"2026-05-20",{"date":65,"type":20},{"date":68,"type":20},"2026-09-20",{"name":70,"class":43},"University of Faisalabad",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":71},"100630471","plantar-pressure-and-acceptance-of-the-leef-shoe-in-individuals-with-diabetes-related-neuropathy-100630471","NCT07488104","Plantar Pressure and Acceptance of the LEEF-shoe in Individuals With Diabetes-related Neuropathy","LEEF-shoe","Inclusion Criteria:\n\n* Aged 18 years or older\n* Diabetes mellitus type 1 or 2\n* IWGDF Risk 2 - 3\n* Prescribed with fully custom-made orthopedic footwear (OS type A)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe foot deformities\n* Active Charcot's neuroarthropathy\n* Foot ulcer or open amputation site\n* Severe illness, based on clinical judgment by the physician\n* Not able to walk at least 10 meters uninterrupted",{"count":80,"type":20},30,[23],"Rationale: Of all individuals with diabetes, 19-34% develop a foot ulcer in their lifetime, and nearly 25% of these ulcers result in amputation. Ulcer prevention is often addressed by prescribing orthopedic shoes (OS). However, the effectiveness of OS is highly dependent on the individual shoe technician's skill and experience, and OS is frequently perceived as unattractive by users.\n\nTo overcome these limitations, the LEEF-shoe was developed. It eliminates the need for a fully individualized shoe technician approach by using a standardized protocol to determine the rocker settings. This may provide comparable plantar pressure relief, while potentially improving patient acceptance due to its more appealing design and simplified prescription process.\n\nObjective: The primary objective is to determine whether the LEEF-shoe differs from standard-OS in terms of plantar pressure distribution. Secondary objectives are evaluation of wearing time and user acceptance of both footwear types.\n\nStudy design: This study is a randomized cross-over trial. Participants will complete pre- and post-tests for plantar pressure distribution, wearing time will be measured, and focus group sessions will assess user experience and acceptance.\n\nStudy population: A total of 30 adults (≥18 years old) with diabetes mellitus and peripheral neuropathy, at increased risk for foot ulceration, will be included.\n\nIntervention:\n\nAll participants will receive two pairs of OS, a standard-OS and an additional OS (e.g., the LEEF-shoe), both provided through usual care channels. At handover, plantar pressure measurements will be performed. Participants will then wear each shoe model for four weeks, one after the other, with wearing time continuously monitored. Following the 8-week period, participants return for a standard control appointment with the OS-technician, during which post-test pressure measurements are taken. Subsequently, participants are allowed to wear either shoe based on personal preference for an additional four weeks, during which wearing time continues to be recorded. The study concludes with focus group sessions to explore experiences and acceptance.\n\nMain study parameters\u002Fendpoints:\n\nThe primary outcome of the study is peak plantar pressure. It will be compared between the standard-OS and LEEF-shoe during the randomization visit. The secondary outcomes are peak plantar pressures in 7 foot regions, wearing time of the OS and user experience and acceptance, assessed through semi-structured focus groups.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will be screened for eligibility during their regular consultation with the prescribing physician and OS-technician. After inclusion, participants will follow standard care procedures, which include an initial shoe fitting, a midway fitting, the handover of both shoes, and two follow-up appointments. To minimize any potential risk associated with wearing the LEEF-shoe at home following the handover, it is required that the LEEF-shoe is at least equivalent to, or better than, the standard-OS in terms of function and safety. Since the LEEF-shoe is produced within the existing framework and standards of OS manufacturing, it is considered a variant of standard-OS and thus falls within the boundaries of standard care.",[26],[85,86,87,88,89],"orthopaedic footwear","Diabetes Mellitus","Diabetic foot","Wearing time","Plantar pressure","RECRUITING","2026-03-18",{"date":93,"type":36},"2026-03-23",{"date":95,"type":20},"2026-04",{"date":97,"type":20},"2027-01-01",{"name":99,"class":43},"University Medical Center Groningen",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":71},"100624014","effects-of-ankle-block-on-postoperative-analgesia-in-diabetic-and-non-diabetic-patients-100624014","NCT07404124","Effects of Ankle Block on Postoperative Analgesia in Diabetic and Non-Diabetic Patients","Comparison of Sensory and Motor Block Characteristics and Postoperative Analgesic Consumption After Ultrasound-Guided Ankle Block in Diabetic and Non-Diabetic Patients Undergoing Lower Extremity Surgery","ANKLE-DM","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Patients scheduled for lower extremity surgery under ultrasound-guided ankle block as part of routine clinical care.\n* Patients able to provide written informed consent.\n* Availability of complete perioperative data including blood glucose levels, -HbA1c values, pain scores, and postoperative analgesic consumption.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Failure of ankle block requiring conversion to another anesthesia technique.\n* Known coagulation disorders contraindicating peripheral nerve block.\n* Active infection at the site of block application.\n* Chronic opioid or analgesic use, chronic alcohol use, or substance abuse.\n* History of diabetic ketoacidosis or hyperosmolar hyperglycemic state.\n* Severe renal or hepatic insufficiency.\n* Known allergy to local anesthetics such as lidocaine or bupivacaine.\n* Inability to perform perioperative blood glucose monitoring.\n* Cognitive impairment or psychiatric conditions interfering with study participation or data collection.",true,{"count":110,"type":20},46,[23],"This prospective observational study aims to evaluate the effects of ultrasound-guided ankle block on sensory and motor block characteristics and postoperative analgesic outcomes in patients undergoing lower extremity surgery. The study will compare diabetic and non-diabetic patients and will also assess the impact of glycemic control on block onset time and postoperative analgesic consumption.\n\nAnkle block is commonly used in patients undergoing foot and ankle surgery, particularly in those with diabetes, peripheral neuropathy, or vascular disease, when general or neuraxial anesthesia may not be suitable. Previous studies suggest that diabetic neuropathy and impaired glycemic control may influence the onset and duration of peripheral nerve blocks.\n\nAdult patients scheduled for lower extremity surgery under ankle block will be included. All procedures will be performed as part of routine clinical care, and no additional interventions will be applied for research purposes. Sensory and motor block onset times, postoperative pain scores, opioid consumption within the first 24 hours, and patient and surgeon satisfaction will be recorded.\n\nThe results of this study are expected to provide clinically relevant information regarding the effects of diabetes and glycemic control on ankle block characteristics and postoperative analgesia.",[86,26,114],"Postoperative Pain Management",[116,117,118,86,26,119,120,121,122,123],"Ankle Block","Ultrasound-Guided Regional Anesthesia","Peripheral Nerve Block","Glycemic Control","Postoperative Analgesia","HBA1C","Lower Extremity Surgery","Opioid Consumption","2026-02-09",{"date":126,"type":36},"2026-02-11",{"date":128,"type":20},"2026-03-01",{"date":130,"type":20},"2026-11-01",{"name":132,"class":43},"Fatih Sultan Mehmet Training and Research Hospital",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":108,"sex":139,"minAge":50,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100611141","vitamin-d-nerve-growth-factor-and-nerve-conduction-studies-in-adult-male-type-2-diabetic-neuropathy-patients-100611141","NCT07236723","Vitamin D, Nerve Growth Factor and Nerve Conduction Studies in Adult Male Type 2 Diabetic Neuropathy Patients","Inclusion Criteria:\n\n* Adult male patients 40 -65 years' old who have type 2 diabetes mellitus on oral hypoglycemic , non-diabetic healthy subjects of matched age and type 2male diabetic neuropathy patients of matched age .\n\nExclusion Criteria:\n\n* Cardiac patients.\n* Patients who have transient ischemic attack or stroke.\n* Patients with inflammatory rheumatic diseases.\n* Patients with malignant diseases.\n* Hyperparathyroidism.\n* Hypothyroidism.\n* Renal impairment with renal replacement therapy.\n* Liver diseases.\n* Patients on vitamin D supplementation.\n* Patients on vitamin B12 supplementation.","MALE","60 Years",{"count":142,"type":20},57,"OBSERVATIONAL","study the relationship of vitamin d with nerve growth factor level and nerve conduction studies in adult male type 2 diabetic neuropathy patients",[26],[147],"vitamin d, nerve growth factor and diabetic neuropathy","2025-11-15",{"date":150,"type":36},"2025-11-19",{"date":152,"type":20},"2025-12",{"date":154,"type":20},"2026-12",{"name":156,"class":43},"Aswan University",2,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":51,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":71},"100609103","additional-effects-of-neural-mobilization-on-pain-balance-and-quality-of-life-in-diabetic-neuropathy-100609103","NCT07210203","Additional Effects of Neural Mobilization on Pain, Balance and Quality of Life in Diabetic Neuropathy","Inclusion Criteria:\n\n* Both genders.\n* Diagnosed cases of Diabetic Peripheral Neuropathy\n* Age 50-75 years.\n* Patients having history of type 2 Diabetes for at least 5 years.\n* Presence of neuropathic symptoms (pain, numbness, tingling, balance issues).\n* Patient having mild to moderate pain according to NPRS\n\nExclusion Criteria:\n\n* Patients with Neurological Disorders like Stroke, multiple sclerosis, Parkinson's disease.\n* Chronic Pain Conditions or Conditions unrelated to DPN (e.g., fibromyalgia, osteoarthritis).\n* Foot Ulcers\u002FInfection: Active ulcers or infections on lower limbs.\n* Uncontrolled Diabetes\n* Severe Balance Impairment Individuals unable to perform basic balance tests (e.g., unable to stand unaided for a few seconds).","50 Years",{"count":166,"type":20},32,[23],"Diabetic Peripheral Neuropathy (DPN) is a common complication of diabetes, affecting up to 50% of patients and causing pain, numbness, and balance impairments, which increase the risk of falls, ulcers, and reduced quality of life. Current treatments mainly manage symptoms, highlighting the need for adjunctive approaches. This randomized controlled trial will evaluate the additional effects of Neural Mobilization (NM) on pain, balance, and quality of life in DPN. Thirty-two patients with type 2 diabetes and DPN will be recruited at Fauji Foundation Hospital and screened using the Michigan Neuropathy Screening Instrument (MNSI). Participants will be randomized into two groups: (1) NM plus Balance Training with standard care and (2) Balance Training alone, each for six weeks (two 30-minute sessions\u002Fweek). Pain will be assessed using the Numeric Pain Rating Scale (NPRS), balance using the Berg Balance Scale, and quality of life using the Norfolk QOL-DN questionnaire. Outcome measures will be recorded at baseline and post-intervention. Ethical approval will be obtained from FUMC ERC, and data will be analyzed using SPSS v.22.",[26,170,171],"Postural Balance","Pain",[59,173,174,175],"Diabetic Peripheral Neuropathy","Postural Pain","Quality of life","2025-09-29",{"date":178,"type":36},"2025-10-07",{"date":180,"type":36},"2024-09-13",{"date":182,"type":20},"2026-01-10",{"name":184,"class":43},"Foundation University Islamabad",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":71},"100604616","glucobites-cookies-gynura-procumbens-for-glycemic-control-and-prevention-of-diabetic-foot-ulcer-risk-in-type-2-diabetes-100604616","NCT07151833","GlucoBites Cookies (Gynura Procumbens) for Glycemic Control and Prevention of Diabetic Foot Ulcer Risk in Type 2 Diabetes","Efficacy of GlucoBites Functional Cookies Containing Gynura Procumbens on Glycemic Control, Insulin Resistance, and Prevention of Diabetic Foot Ulcer Risk in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial","GlucoBites","Inclusion Criteria:\n\n* Adults aged 20-70 years.\n* Diagnosed with type 2 diabetes mellitus (T2DM) based on ADA criteria.\n* HbA1c ≥ 7%.\n* At risk of diabetic foot ulcer (ABI \\\u003C 0.9 or early neuropathy signs).\n* Willing to consume study cookies and comply with study protocol.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Current use of herbal supplements or functional foods containing Gynura procumbens.\n* Presence of active diabetic foot ulcer or severe infection.\n* Severe cardiovascular, renal (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²), or hepatic impairment.\n* Pregnancy or breastfeeding.\n* Known allergy to ingredients in study cookies.\n* Participation in another clinical trial within the last 3 months.","20 Years","70 Years",{"count":196,"type":20},126,[23],"The goal of this randomized controlled trial is to learn if GlucoBites functional cookies containing Gynura procumbens can help improve blood sugar control and lower the risk of diabetic foot ulcers in adults with type 2 diabetes.\n\nThe main questions are:\n\n* Do GlucoBites cookies lower fasting blood glucose and HbA1c?\n* Do GlucoBites cookies improve insulin resistance and vascular health?\n* Can GlucoBites reduce early signs that may lead to diabetic foot ulcers?\n\nResearchers will compare:\n\n* Intervention group: participants will eat 4 GlucoBites cookies every day for 12 weeks.\n* Control group: participants will continue standard diabetes care without GlucoBites.\n\nParticipants will:\n\n* Visit the community health center for blood tests and foot health checks.\n* Be monitored for blood sugar, insulin resistance, lipid profile, and vascular function.\n* Be assessed for early risk of diabetic foot ulcer development.\n\nThis study will help determine if a functional food innovation can support diabetes care and prevent complications.",[200,26],"Type 2 Diabetes Mellitus",[202,203,204,119,205,206],"Diabetes Mellitus Type 2","Functional Food","Gynura procumbens","Insulin Resistance","Diabetic Foot Ulcer Prevention","2025-09-02",{"date":209,"type":36},"2025-09-03",{"date":211,"type":20},"2025-09-20",{"date":213,"type":20},"2026-01-20",{"name":215,"class":43},"Andina Setyawati",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":71},"100595772","phase-2-effect-of-melatonin-in-patients-with-diabetic-peripheral-neuropathy-100595772","NCT07036796","Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy","Effect of Melatonin on the Clinical Outcomes in Type 2 Diabetic Patients With Peripheral Neuropathy","Inclusion Criteria:\n\n1. Patients aged 40-75 years diagnosed with type 2 DM.\n2. Diabetes duration at least 1 year.\n3. Patients diagnosed with diabetic peripheral neuropathy.\n4. Stable antidiabetic medication for at least 1 month before enrollment and during the trial\n\nExclusion Criteria:\n\n1. Patients with autoimmune disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients.\n2. Patients with severe kidney or liver dysfunction.\n3. Patients diagnosed with neurodegenerative diseases.\n4. Active infection.\n5. Use of medications or supplements known to cause or treat peripheral neuropathy.\n6. Alcohol consumption or substance abuse.\n7. Patients consuming any antioxidant supplements or anti-inflammatory medicines during or 3 months before enrollment.\n8. Pregnancy or lactation or expecting to get pregnant during the study.\n9. Allergy to melatonin.",{"count":224,"type":20},60,[226],"PHASE2","The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.",[173,26,229],"Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients",[231,232,233,234],"Diabetic peripheral neuropathy","Diabetic neuropathies","Diabetic neuropathy in type 2 diabetes","Melatonin","2025-08-05",{"date":237,"type":36},"2025-08-06",{"date":239,"type":36},"2025-07-04",{"date":241,"type":20},"2026-07-04",{"name":243,"class":43},"Ain Shams University",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":266,"locationsCount":157},"100589737","the-relation-between-diabetic-neuropathy-and-muscle-mass-in-type-2-diabetes-mellitus-patients-100589737","NCT06958302","The Relation Between Diabetic Neuropathy and Muscle Mass in Type 2 Diabetes Mellitus Patients","Inclusion Criteria:\n\n* The study group consisted of patients diagnosed with Type 2 diabetes mellitus aged ≥45 years old\n\nExclusion Criteria:\n\n* Type 1 DM, gestational diabetes mellitus\n* Severe cardiopulmonary disease, significant\u002Fprevious neurological disorder (e.g., ischemic stroke, Parkinson disease) causing difficulty during daily activities (e.g., walking), visual deficit, and psychiatric problem\n* Other neuropathy-associated factors such as: alcohol, nutrition, poisoning and drug addiction\n* Patients with renal diseases, malignancy and autoimmune diseases\n* Patients on long term use of Steroids","45 Years",{"count":224,"type":20},"The goal of this observational study is to evaluate the relation between diabetic neuropathy in type 2 diabetes mellitus patients and muscle mass",[26,254],"Sarcopenia",[256,257,258,259],"diabetic neuropathy","muscle mass","sarcopenia","nerve conduction studies","2025-04-26",{"date":262,"type":36},"2025-05-06",{"date":264,"type":20},"2025-05-30",{"date":38,"type":20},{"name":243,"class":43},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":71},"100550887","clinical-outcomes-related-to-treatment-of-distal-symmetric-polyneuropathy-using-semiconductor-embedded-therapeutic-socks-100550887","NCT06452914","Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks","Inclusion Criteria:\n\n* Patients diagnosed with mild to moderate Diabetic Neuropathy with a score between 2 and 7 out of 10 on the MNSI upon clinical examination and assessment.\n* Patients reporting symptoms of Diabetic Neuropathy\n* Patients age 18-79\n* Patients who are willing and able to adhere to follow-up schedule and protocol guidelines\n* Patients who are willing and able to sign corresponding research subject consent form\n\nExclusion Criteria:\n\n* Patient has a history of neurodegenerative conditions, including multiple sclerosis or Parkinson's disease\n* Patient has chronic pain conditions unrelated to diabetic neuropathy, including spinal stenosis, low back pain, and sciatica\n* Patient has auto-immune or auto-inflammatory diseases other than Diabetic Neuropathy, including Multiple Sclerosis or Lyme Disease\n* Patient has experienced a stroke\n* Patient has any type of paralysis\n* Patients with a score less than 2 and greater than 7 out of 10 on the MNSI upon clinical examination and assessment\n* Patient has severe peripheral artery disease (with an ankle brachial index of \\\u003C0.7)\n* Patient has chronic venous insufficiency (greater than stage 4)\n* Patient has used tobacco within the last 90 days\n* Patient has an open wound at the area of application\n* Patient has started a new medication for diabetic neuropathy symptoms within the past 90 days\n* Patient is not within the ages of 18-79\n* Patient is unwilling or unable to sign the corresponding research subject consent form\n* Patient meets any other criteria or has any other condition that, in the opinion of the investigator, would prevent them from completing the study or that, in the opinion of the investigator, would confound study results","79 Years",{"count":275,"type":20},80,[23],"Distal symmetric polyneuropathy, also known as diabetic neuropathy, is the most common neurological complication of diabetes and a main cause of morbidity. The condition leads to gradual loss of function of the longest nerve fibers that limits function and decreases quality of life. Symptoms present distally and symmetrically in toes and feet. Symptoms of the neurologic disability include sensory loss, risk of foot ulcers and limb amputations and pain. The condition is not generally considered reversible, and condition management aims to slow progression and prevent complications.\n\nAccording to estimates from the International Diabetes Federation, diabetic neuropathy affected approximately 425 million people in 2017, with projections indicating a rise to 628 million by 2045. Despite the high prevalence of this condition, it is commonly misdiagnosed and has limited treatment options. There are multiple phenotypes of diabetic neuropathy, with the most common form being distal symmetric sensorimotor polyneuropathy, which is what we will be focusing on in this study.\n\nThe proposed study seeks to evaluate the effectiveness of a non-compressive therapeutic socks throughout a 12-week course of rehabilitation for managing distal symmetric polyneuropathy. Outcome measures will be collected at standard intervals and compared with pre-treatment measures to evaluate effectiveness of treatment.",[26],"2025-02-24",{"date":281,"type":36},"2025-02-25",{"date":283,"type":36},"2024-06-11",{"date":285,"type":20},"2025-06",{"name":287,"class":288},"Endocrine Research Solutions","INDUSTRY",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":194,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":71},"100567471","effect-of-reiki-on-neuropathic-pain-severity-and-sleep-quality-in-patients-with-diabetic-neuropathy-100567471","NCT06668623","Effect of Reiki on Neuropathic Pain Severity and Sleep Quality in Patients With Diabetic Neuropathy","Inclusion Criteria:\n\n* Over 18 years of age\n* No communication problems\n* Communicating in Turkish\n* No diagnosis of mental illness\n* Willingness to participate in the study\n* Being competent enough to answer forms and surveys\n* VAS pain intensity 3 and above\n* 4 Question Neuropathic Pain score 4 and above\n* Not having received Reiki treatment\n\nExclusion Criteria:\n\n* Receiving a different illness and treatment during the therapy process\n* Leaving Reiki practice\n* Psychiatric illness\n* Becoming a Reiki practitioner or instructor\n* Cerebrovascular disease\n* Receiving Reiki practice",{"count":224,"type":20},[23],"The study is planned to be conducted in a mixed research design with quantitative and qualitative types. The quantitative phase of the study was planned as a single-blind, randomized controlled study with Reiki group, Sham Reiki group and control group designs in order to examine the effect of second-level (remote application) Reiki applied to patients with diabetic neuropathy for 20 minutes a day for four days on pain intensity, neuropathic pain intensity (DN4 Questionnaire) total scores and sleep quality. The qualitative study will be conducted with 4 people from the Reiki and Sham Reiki groups, a total of 8 patients, one week after the application, using the individual in-depth interview method and a semi-structured questionnaire.",[26],[26,171,300,301],"Sleep Quality","Reiki","2025-02-13",{"date":304,"type":36},"2025-02-14",{"date":306,"type":36},"2024-11-01",{"date":308,"type":20},"2025-12-30",{"name":310,"class":43},"TC Erciyes University"]